KRAS G13D

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colorectal Adenocarcinoma1
KRAS G13D	Cetuximab + ChemotherapyCombination	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11054 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma2
KRAS G13D	Erlotinib	Predictive	C	Supports Resistance	—	submitted	EID3892 In a retrospective study of 274 stage IIIB or IV non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (25/55) treated with erlotinib plus chemotherapy were associated with decreas…

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Colorectal Adenocarcinoma1

KRAS G13D

Cetuximab + ChemotherapyCombination

Predictive

Does Not Support Sensitivity Response

submitted

EID11054

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma2

KRAS G13D

Erlotinib

Predictive

Supports Resistance

—

submitted

EID3892

In a retrospective study of 274 stage IIIB or IV non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (25/55) treated with erlotinib plus chemotherapy were associated with decreas…

Malignant Breast Neoplasm1
KRAS G13D	Pictilisib	Predictive	D	Supports Resistance	4	accepted	EID2041 This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic

Malignant Breast Neoplasm1

KRAS G13D

Pictilisib

Predictive

Supports Resistance

accepted

EID2041

This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

civic

Malignant Colon Neoplasm4
KRAS G13D	Cetuximab	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID6974 In a two armed Phase II study of 53 patients with molecularly selected G13D mutant, chemotherapy-refractory metastatic CRC, 25 patients were treated with cetuximab monotherapy, and 28 with cetuximab a… (full text at CIViC) PMID 27114605 · Segelov et al., 2016 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3896 In a phase 3 clinical study,�BRAF wild-type stage III colon cancer patients harboring KRAS G13D mutation (n=220) and treated with cetuximab plus chemotherapy were associated with decreased disease-fre… (full text at CIViC) PMID 24687927 · Yoon et al., 2014 · Open in CIViC	civic
KRAS G13D	Pan-RAF/MEK Molecular Glue NST-628	Predictive	D	Supports Sensitivity Response	4	submitted	EID13157 In KRAS G13D-mutant HCT116 cells, NST-628 inhibited proliferation, increased apoptosis, and produced durable suppression of phospho-ERK. In HCT116 xenografts, NST-628 suppressed phospho-MEK and phosph… (full text at CIViC) PMID 38588399 · Ryan et al., 2024 · Open in CIViC	civic
KRAS G13D	Regorafenib Anhydrous	Predictive	D	Supports Sensitivity Response	—	submitted	EID3897 In an in vitro study, a DLD-1 cell line expressing KRAS G13D mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-type KRAS. Resist… (full text at CIViC) PMID 26865419 · Takigawa et al., 2016 · Open in CIViC	civic

Malignant Colon Neoplasm4

KRAS G13D

Cetuximab

Predictive

Does Not Support Sensitivity Response

submitted

EID6974

In a two armed Phase II study of 53 patients with molecularly selected G13D mutant, chemotherapy-refractory metastatic CRC, 25 patients were treated with cetuximab monotherapy, and 28 with cetuximab a… (full text at CIViC)

PMID 27114605 · Segelov et al., 2016 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3896

In a phase 3 clinical study,�BRAF wild-type stage III colon cancer patients harboring KRAS G13D mutation (n=220) and treated with cetuximab plus chemotherapy were associated with decreased disease-fre… (full text at CIViC)

PMID 24687927 · Yoon et al., 2014 · Open in CIViC

civic

KRAS G13D

Pan-RAF/MEK Molecular Glue NST-628

Predictive

Supports Sensitivity Response

submitted

EID13157

In KRAS G13D-mutant HCT116 cells, NST-628 inhibited proliferation, increased apoptosis, and produced durable suppression of phospho-ERK. In HCT116 xenografts, NST-628 suppressed phospho-MEK and phosph… (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

civic

KRAS G13D

Regorafenib Anhydrous

Predictive

Supports Sensitivity Response

—

submitted

EID3897

In an in vitro study, a DLD-1 cell line expressing KRAS G13D mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-type KRAS. Resist… (full text at CIViC)

PMID 26865419 · Takigawa et al., 2016 · Open in CIViC

civic

Malignant Colorectal Neoplasm30
KRAS G12 OR KRAS G13D	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	3	accepted	EID6292 This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + … (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Sensitivity Response	4	accepted	EID306 KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS. PMID 20978259 · De Roock et al., 2010 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Does Not Support Resistance	2	accepted	EID806 This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of … (full text at CIViC) PMID 26623049 · Osumi et al., 2015 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Resistance	3	accepted	EID1180 12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free… (full text at CIViC) PMID 26371285 · Schirripa et al., 2015 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Resistance	4	accepted	EID1181 Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colore… (full text at CIViC) PMID 26812186 · Rowland et al., 2016 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Resistance	—	submitted	EID3879 In a retrospective study of 23 EGFR-expressing metastatic colorectal cancer patients, patients with KRAS codon G12 or G13 mutations (n=6) treated with cetuximab were associated with decreased partial … (full text at CIViC) PMID 17363584 · Benvenuti et al., 2007 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Resistance	3	accepted	EID3881 This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Resistance	—	accepted	EID3882 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	B	Supports Resistance	—	submitted	EID3884 In a phase 3 clinical study of 533 metastatic colorectal cancer patients, patients harboring KRAS G13D mutation and treated with cetuximab plus standard chemotherapy (n=42) were associated with reduce… (full text at CIViC) PMID 22734028 · Tejpar et al., 2012 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3873 In a retrospective study of 89 metastatic irinotecan-refractory colorectal cancer patients, patients with a KRAS codon 12 or 13 mutation (n=24) treated with cetuximab plus chemotherapy were associated… (full text at CIViC) PMID 18202412 · Lièvre et al., 2008 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3874 In a retrospective study of 59 metastatic, chemotherapy-refractory, colorectal cancer patients, patients with a KRAS exon 2 mutation (n=22) treated with cetuximab and standard chemotherapy were assoc… (full text at CIViC) PMID 17375050 · Di Fiore et al., 2007 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3875 In a retrospective study of 113 metastatic irinotecan-refractory colorectal cancer patients, patients with a KRAS codon 12 or 13 mutation treated with cetuximab plus irinotecan (34/83) were associated… (full text at CIViC) PMID 17998284 · De Roock et al., 2008 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3876 In a retrospective study of 30 metastatic colorectal cancer patients, patients with a KRAS codon 12 or 13 mutation (n=13) treated with cetuximab and standard chemotherapy were associated with an absen… (full text at CIViC) PMID 16618717 · Lièvre et al., 2006 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	rejected	EID3877 In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3880 In a retrospective study of 572 advanced colorectal cancer patients, patients treated with cetuximab and best supportive care with a KRAS exon 2 mutation (81/164) were associated with reduced response… (full text at CIViC) PMID 18946061 · Karapetis et al., 2008 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3883 In a retrospective study of 32 metastatic colorectal cancer patients, a patient with KRAS G13D mutation treated with cetuximab was reported to be a non-responder, whereas none of the 10 partial respon… (full text at CIViC) PMID 18669866 · Perrone et al., 2009 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3885 In a phase 3 clinical study of 1,198 metastatic colorectal cancer patients, patients harboring KRAS codon 12 or 13 mutations and treated with cetuximab plus FOLFIRI were associated with reduced overal… (full text at CIViC) PMID 21502544 · Van Cutsem et al., 2011 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3886 In a phase 2 clinical study of 344 metastatic colorectal cancer patients, patients harboring KRAS codon 12 or 13 mutations and treated with cetuximab plus FOLFOX-4 (n=52) were associated with reduced … (full text at CIViC) PMID 19114683 · Bokemeyer et al., 2009 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3887 In a retrospective study of 95 metastatic colorectal cancer patients, patients harboring KRAS activating mutation (n=33) and treated with cetuximab plus standard chemotherapy were reportedly non-respo… (full text at CIViC) PMID 20010090 · Yen et al., 2010 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID3888 In a phase 3 clinical study (NCT00154102) of 1198 metastatic colorectal cancer patients, patients harboring KRAS codon 12 or 13 mutations and treated with cetuximab plus FOLFIRI (n=105) were associate… (full text at CIViC) PMID 19339720 · Van Cutsem et al., 2009 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	D	Supports Sensitivity Response	4	accepted	EID145 Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model. PMID 20978259 · De Roock et al., 2010 · Open in CIViC	civic
KRAS G13D	Cetuximab	Predictive	D	Supports Resistance	—	accepted	EID3878 In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wil… (full text at CIViC) PMID 22722830 · Misale et al., 2012 · Open in CIViC	civic
KRAS G13D	Cetuximab + PanitumumabSubstitutes	Predictive	C	Does Not Support Resistance	2	accepted	EID6320 In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic
KRAS G13D	Dactolisib + SelumetinibCombination	Predictive	D	Supports Sensitivity Response	2	accepted	EID2183 In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/… (full text at CIViC) PMID 22392911 · Migliardi et al., 2012 · Open in CIViC	civic
KRAS G13D	Dual IGF-1R/InsR Inhibitor BMS-754807	Predictive	D	Supports Resistance	3	submitted	EID7076 The results showed that cell lines with BRAF(V600E) or KRAS(G13D) mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF were particularly sensitive to BMS-754807 if they hav… (full text at CIViC) PMID 25527633 · Huang et al., 2015 · Open in CIViC	civic
KRAS G13D	Palbociclib	Predictive	D	Supports Sensitivity Response	—	submitted	EID3891 In an in vitro study, a Lovo cell line expressing KRAS G13D mutation was associated with sensitivity to palbociclib treatment as compared to cells treated with DMSO control. Sensitivity was determine… (full text at CIViC) PMID 27167191 · Lee et al., 2016 · Open in CIViC	civic
KRAS G13D	Panitumumab	Predictive	C	Supports Resistance	3	accepted	EID2178 Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for N… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
KRAS G13D	Cetuximab + PanitumumabSubstitutes	Predictive	C	Supports Resistance	2	accepted	EID6322 In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic
KRAS G13D	Regorafenib Anhydrous	Predictive	D	Supports Resistance	1	accepted	EID3889 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
KRAS G13D	Sunitinib	Predictive	D	Supports Resistance	—	submitted	EID3890 In an in vitro study, colorectal cancer SW48 cell line expressing KRAS G13D mutation demonstrated reduced sensitivity to sunitinib treatment (IC50: 3.4uM vs. 2.6uM, P<0.05) compared to SW48 cells expr… (full text at CIViC) PMID 23455880 · Modest et al., 2013 · Open in CIViC	civic

Malignant Colorectal Neoplasm30

KRAS G12 OR KRAS G13D

(prognostic)

Prognostic

Does Not Support Poor Outcome

accepted

EID6292

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Sensitivity Response

accepted

EID306

KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.

PMID 20978259 · De Roock et al., 2010 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Does Not Support Resistance

accepted

EID806

This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of … (full text at CIViC)

PMID 26623049 · Osumi et al., 2015 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

accepted

EID1180

12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free… (full text at CIViC)

PMID 26371285 · Schirripa et al., 2015 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

accepted

EID1181

Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colore… (full text at CIViC)

PMID 26812186 · Rowland et al., 2016 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3879

In a retrospective study of 23 EGFR-expressing metastatic colorectal cancer patients, patients with KRAS codon G12 or G13 mutations (n=6) treated with cetuximab were associated with decreased partial … (full text at CIViC)

PMID 17363584 · Benvenuti et al., 2007 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

accepted

EID3881

This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

accepted

EID3882

In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC)

PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3884

In a phase 3 clinical study of 533 metastatic colorectal cancer patients, patients harboring KRAS G13D mutation and treated with cetuximab plus standard chemotherapy (n=42) were associated with reduce… (full text at CIViC)

PMID 22734028 · Tejpar et al., 2012 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3873

In a retrospective study of 89 metastatic irinotecan-refractory colorectal cancer patients, patients with a KRAS codon 12 or 13 mutation (n=24) treated with cetuximab plus chemotherapy were associated… (full text at CIViC)

PMID 18202412 · Lièvre et al., 2008 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3874

In a retrospective study of 59 metastatic, chemotherapy-refractory, colorectal cancer patients, patients with a KRAS exon 2 mutation (n=22) treated with cetuximab and standard chemotherapy were assoc… (full text at CIViC)

PMID 17375050 · Di Fiore et al., 2007 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3875

In a retrospective study of 113 metastatic irinotecan-refractory colorectal cancer patients, patients with a KRAS codon 12 or 13 mutation treated with cetuximab plus irinotecan (34/83) were associated… (full text at CIViC)

PMID 17998284 · De Roock et al., 2008 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3876

In a retrospective study of 30 metastatic colorectal cancer patients, patients with a KRAS codon 12 or 13 mutation (n=13) treated with cetuximab and standard chemotherapy were associated with an absen… (full text at CIViC)

PMID 16618717 · Lièvre et al., 2006 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

rejected

EID3877

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3880

In a retrospective study of 572 advanced colorectal cancer patients, patients treated with cetuximab and best supportive care with a KRAS exon 2 mutation (81/164) were associated with reduced response… (full text at CIViC)

PMID 18946061 · Karapetis et al., 2008 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3883

In a retrospective study of 32 metastatic colorectal cancer patients, a patient with KRAS G13D mutation treated with cetuximab was reported to be a non-responder, whereas none of the 10 partial respon… (full text at CIViC)

PMID 18669866 · Perrone et al., 2009 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3885

In a phase 3 clinical study of 1,198 metastatic colorectal cancer patients, patients harboring KRAS codon 12 or 13 mutations and treated with cetuximab plus FOLFIRI were associated with reduced overal… (full text at CIViC)

PMID 21502544 · Van Cutsem et al., 2011 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3886

In a phase 2 clinical study of 344 metastatic colorectal cancer patients, patients harboring KRAS codon 12 or 13 mutations and treated with cetuximab plus FOLFOX-4 (n=52) were associated with reduced … (full text at CIViC)

PMID 19114683 · Bokemeyer et al., 2009 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3887

In a retrospective study of 95 metastatic colorectal cancer patients, patients harboring KRAS activating mutation (n=33) and treated with cetuximab plus standard chemotherapy were reportedly non-respo… (full text at CIViC)

PMID 20010090 · Yen et al., 2010 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

submitted

EID3888

In a phase 3 clinical study (NCT00154102) of 1198 metastatic colorectal cancer patients, patients harboring KRAS codon 12 or 13 mutations and treated with cetuximab plus FOLFIRI (n=105) were associate… (full text at CIViC)

PMID 19339720 · Van Cutsem et al., 2009 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Sensitivity Response

accepted

EID145

Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.

PMID 20978259 · De Roock et al., 2010 · Open in CIViC

civic

KRAS G13D

Cetuximab

Predictive

Supports Resistance

—

accepted

EID3878

In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wil… (full text at CIViC)

PMID 22722830 · Misale et al., 2012 · Open in CIViC

civic

KRAS G13D

Cetuximab + PanitumumabSubstitutes

Predictive

Does Not Support Resistance

accepted

EID6320

In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC)

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

civic

KRAS G13D

Dactolisib + SelumetinibCombination

Predictive

Supports Sensitivity Response

accepted

EID2183

In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

civic

KRAS G13D

Dual IGF-1R/InsR Inhibitor BMS-754807

Predictive

Supports Resistance

submitted

EID7076

The results showed that cell lines with BRAF(V600E) or KRAS(G13D) mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF were particularly sensitive to BMS-754807 if they hav… (full text at CIViC)

PMID 25527633 · Huang et al., 2015 · Open in CIViC

civic

KRAS G13D

Palbociclib

Predictive

Supports Sensitivity Response

—

submitted

EID3891

In an in vitro study, a Lovo cell line expressing KRAS G13D mutation was associated with sensitivity to palbociclib treatment as compared to cells treated with DMSO control. Sensitivity was determine… (full text at CIViC)

PMID 27167191 · Lee et al., 2016 · Open in CIViC

civic

KRAS G13D

Panitumumab

Predictive

Supports Resistance

accepted

EID2178

Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for N… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

civic

KRAS G13D

Cetuximab + PanitumumabSubstitutes

Predictive

Supports Resistance

accepted

EID6322

PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC

civic

KRAS G13D

Regorafenib Anhydrous

Predictive

Supports Resistance

accepted

EID3889

In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC)

PMID 26161928 · Camaj et al., 2015 · Open in CIViC

civic

KRAS G13D

Sunitinib

Predictive

Supports Resistance

—

submitted

EID3890

In an in vitro study, colorectal cancer SW48 cell line expressing KRAS G13D mutation demonstrated reduced sensitivity to sunitinib treatment (IC50: 3.4uM vs. 2.6uM, P<0.05) compared to SW48 cells expr… (full text at CIViC)

PMID 23455880 · Modest et al., 2013 · Open in CIViC

civic

Solid Tumors, Advanced1unmapped disease
KRAS G12C OR KRAS G12D OR KRAS G13D OR RET M918T OR KRAS G12A OR KRAS G12V OR KRAS G12R OR KRAS Amplification OR KRAS G12S OR KRAS G13R OR KRAS G12P	Sorafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12700 In the randomized discontinuation Phase II MOST-Plus trial of advanced/metastatic solid tumors with sorafenib-targeted somatic alterations (NCT02029001; n = 35 randomized; KRAS G12A/C/D/P/R/S/V n = 29… (full text at CIViC) PMID 37444551 · Trédan et al., 2023 · Open in CIViC	civic

Solid Tumors, Advanced1unmapped disease

KRAS G12C OR KRAS G12D OR KRAS G13D OR RET M918T OR KRAS G12A OR KRAS G12V OR KRAS G12R OR KRAS Amplification OR KRAS G12S OR KRAS G13R OR KRAS G12P

Sorafenib

Predictive

Supports Sensitivity Response

submitted

EID12700

In the randomized discontinuation Phase II MOST-Plus trial of advanced/metastatic solid tumors with sorafenib-targeted somatic alterations (NCT02029001; n = 35 randomized; KRAS G12A/C/D/P/R/S/V n = 29… (full text at CIViC)

PMID 37444551 · Trédan et al., 2023 · Open in CIViC

civic

Evidence by cancer (39 items)

Clinical significance (0)